0.7785

3.99% 0.0299

Spero Therapeutics Inc (SPRO)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$0.7486

Offen:

$0.75

24-Stunden-Volumen:

44,946

Relative Volume:

0.22

Marktkapitalisierung:

$42.44M

Einnahmen:

$76.19M

Nettoeinkommen (Verlust:

$-1.61M

KGV:

77.85

EPS:

0.01

Netto-Cashflow:

$28.98M

1W Leistung:

-1.21%

1M Leistung:

-4.68%

6M Leistung:

-43.18%

1J Leistung:

-53.10%

1-Tages-Spanne:

$0.75

$0.7785

1-Wochen-Bereich:

$0.73

$0.80

52-Wochen-Spanne:

$0.73

$1.89

Spero Therapeutics Inc Stock (SPRO) Company Profile

Firmenname

Spero Therapeutics Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (679)

Telefon

857-242-1600

Adresse

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Mitarbeiter

Twitter

@spero_tx

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

SPRO's Discussions on Twitter

Vergleichen Sie SPRO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SPRO Spero Therapeutics Inc	0.7785	42.44M	76.19M	-1.61M	28.98M	0.01
VRTX Vertex Pharmaceuticals Inc	502.92	129.14B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	680.61	74.41B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	581.21	35.31B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.75	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	254.57	27.35B	3.32B	-860.46M	-1.04B	-8.32

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-12-20	Herabstufung	Evercore ISI	Outperform → In-line
2022-09-23	Hochstufung	Evercore ISI	In-line → Outperform
2021-10-01	Herabstufung	Oppenheimer	Outperform → Perform
2021-01-22	Bestätigt	H.C. Wainwright	Buy
2020-12-16	Eingeleitet	Berenberg	Buy
2020-09-29	Eingeleitet	Evercore ISI	Outperform
2019-11-05	Bestätigt	H.C. Wainwright	Buy
2019-09-09	Eingeleitet	Janney	Buy
2018-02-09	Eingeleitet	Cantor Fitzgerald	Overweight
2017-11-27	Eingeleitet	BofA/Merrill	Neutral
2017-11-27	Eingeleitet	Oppenheimer	Outperform
2017-11-27	Eingeleitet	Stifel	Buy

Alle ansehen

Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten

Mar 11, 2025

Spero Therapeutics stock hits 52-week low at $0.74 amid challenges - Investing.com

Mar 11, 2025

Mar 07, 2025

Spero Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView

Mar 07, 2025

Mar 06, 2025

Spero Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025

Mar 05, 2025

Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Wednesday - Defense World

Mar 05, 2025

Mar 04, 2025

Non- Tuberculous Mycobacterial Infections Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharma - Barchart

Mar 04, 2025

Mar 01, 2025

Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN

Mar 01, 2025

Spero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia

Mar 01, 2025

Spero Therapeutics faces Nasdaq delisting over share price - Investing.com India

Mar 01, 2025

Feb 25, 2025

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 25, 2025

UPDATESpero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - The Manila Times

Feb 25, 2025

Marjorie Taylor Greene Is Betting Big on Palantir Stock. Should You? - The Globe and Mail

Feb 25, 2025

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 25, 2025

Rare Disease Biotech Spero Therapeutics Takes Stage at Major TD Cowen Healthcare Conference - StockTitan

Feb 25, 2025

Can Spero Therapeutics' Rare Disease Pipeline Impress Investors at Major Healthcare Conference? - StockTitan

Feb 25, 2025

Feb 07, 2025

Spero Therapeutics COO Timothy Keutzer sells shares for $44,097 - MSN

Feb 07, 2025

Feb 06, 2025

Spero therapeutics CFO sells $16,137 in stock By Investing.com - Investing.com Nigeria

Feb 06, 2025